LNTH News and Press, Lantheus Holdings Inc. From 10/12/23

2023-10-12 16:35:30 ET Summary Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, has driven significant revenue growt...

2023-10-03 08:41:53 ET Gainers: Alx Oncology ( ALXO ) +116% . Vericity  ( VERY ) +95% Strengthens Individual Insurance Presence in the United States with the Acquisition of Vericity. POINT Biopharma Global  ( PNT ) +85% to acquire Point ...

2023-09-21 11:04:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re putting together a list of overlooked AI stocks, I wouldn’t try to sneak Nvidia (NASDAQ: NVDA ) on it. Even investor neophytes know about CEO Jensen Huan...

2023-09-20 14:13:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artificial intelligence is still all the rage with investors, but the hype has pushed many stocks to unsustainable heights. Now that the irrational frenzy is cooling off, some compelling opport...

BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, an...

2023-08-30 16:00:30 ET Summary Lantheus Holdings, Inc. stock sold off sharply after Q2 numbers, and is now trading at July '22 range. Q2 earnings showed solid growth, but LNTH's economic profitability and market technicals are concerning. LNTH divested its RELISTOR royalties, ...

2023-08-30 08:20:15 ET Summary Radiopharmacy is expected to experience exponential growth over the next decade. Radiopharmaceutical-based therapies offer more targeted and specific approaches for cancer treatment and medical imaging, with prostate cancer proving to be a particular...

2023-08-18 08:43:41 ET More on Lantheus Lantheus: Pylarify And Definity Driving Strong Growth POINT Biopharma slips after pipeline update Lantheus prostate cancer diagnostics recommended for EU approval Lantheus soars 15% on Q1 beat, beats Q2 and FY forecast ...

2023-08-14 10:46:36 ET More on POINT Biopharma POINT Biopharma: Leading The Future Of Radioligand Therapy POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financ...

2023-08-03 16:16:02 ET Lantheus Holdings, Inc. (LNTH) Q2 2023 Earnings Conference Call August 03, 2023 08:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President ...